Therapy News and Research

RSS

Also in global health news: ART access in Zimbabwe; Indonesia bird flu deaths; Kenya floods; Solomon Island tsunami

Zimbabwe's government plans work with international organizations to increase the number of people receiving anti-retroviral therapy (ART) to 300,000 by the end of the year, up from the 180,000 who currently get the drugs, Henry Madzorera, the country's health minister, said on Tuesday, ZimOnline reports.

6 Jan 2010

Physicians perform first implantation of leadless cardiac monitoring device for detecting arrhythmias

BIOTRONIK SE & Co. KG, the pioneer of wireless remote monitoring technologies and leading manufacturer of implantable cardiac devices, today announced the first implantations of BIOTRONIK’s new leadless cardiac monitoring device performed by a team of physicians led by Professor Dr. Gerhard Hindricks, Director, Electrophysiology Department at the Leipzig Heart Center in Leipzig, Germany.

6 Jan 2010

Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a recent "refuse to file" (RTF) letter issued by the Food and Drug Administration (FDA) regarding Merck Serono's oral cladribine has heightened the competition between oral cladribine and its primary competitor, Novartis/Mitsubishi Tanabe's FTY-720 (fingolimod), to be the first oral disease-modifying multiple sclerosis therapy to reach the market in the United States.

6 Jan 2010

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

A comprehensive appraisal of the management and treatment options for low-risk prostate cancer found that the rates of survival and tumor recurrence are similar among the most common treatment approaches, although costs can vary considerably.

6 Jan 2010

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.

6 Jan 2010

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI), including stenting, treatment with Effient(®) (prasugrel) compared with branded clopidogrel (Plavix(®)) was more cost effective, and in most cases cost saving.

6 Jan 2010

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

Sexual function in prostate cancer patients receiving external beam radiation therapy (EBRT) decreases within the first two years after treatment but then stabilizes and does not continuously decline as was previously thought, according to a study in the January 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

6 Jan 2010

Center for Technology and Aging announces grants to improve medication use in older adults

The Center for Technology and Aging today announced grants to five organizations for projects that promise to help improve medication use in older adults with chronic health conditions.

6 Jan 2010

U.S. market for urological devices to reach over $5.4 billion in 2016

According to a new global report series by iData Research, the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for urological devices is estimated to more than double in value by 2016, reaching over $5.4 billion.

6 Jan 2010

New survival prediction equation may impact clinical trials for treating PAH

Setting out to determine the survival of patients with pulmonary arterial hypertension (PAH), researchers at the University of Chicago Medical Center and their colleagues also discovered that an equation used for more than 20 years to predict survival is outdated.

6 Jan 2010

Loyola University Health System launches new program to study healthcare, costs and patient safety

Loyola University Health System has established a new Program in Health Services Research to study how doctors and nurses can provide better health care at lower costs to more people.

6 Jan 2010

UC San Diego bioengineering professor receives 2009 Presidential Science Prize

For Shu Chien - a pioneer in the growing field of bioengineering - understanding and learning the marvels of how the human body works has been the foundation of his decades-long quest to advance science and technology worldwide. The UC San Diego bioengineering professor's significant scientific endeavors have paved the way for recognition of his renowned work at the university's Jacobs School of Engineering and abroad.

6 Jan 2010

AMT receives Innovation Credit to develop gene therapy treatment for DMD

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that it will receive an Innovation Credit of up to EUR 4 million from the Dutch government to support the development of AMT's gene therapy treatment for Duchenne Muscular Dystrophy (DMD).

6 Jan 2010

Animal experiments show old antidepressant may reverse heart failure

A team of Johns Hopkins and other researchers have found in animal experiments that an antidepressant developed over 40 years ago can blunt and even reverse the muscle enlargement and weakened pumping function associated with heart failure.

6 Jan 2010

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe.

6 Jan 2010

Lerner Medical Devices' Levia receives FDA clearance

Lerner Medical Devices, Inc. announced today that Levia®, a novel, in-home, ultraviolet B (UVB) phototherapy device, has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for treatment of psoriasis and certain other skin conditions such as vitiligo.

6 Jan 2010

Health Canada approves Zyclara Cream for multiple actinic keratoses

Health Canada has approved Zyclara™ (imiquimod) Cream 3.75%, a topical prescription treatment for multiple actinic keratoses (AK) located on the face or balding scalp in adults. Actinic Keratosis is a common skin condition that can lead to squamous cell carcinoma, a form of non-melanoma skin cancer, if left untreated.

6 Jan 2010

Bioheart signs distribution agreements to market Home Heart Failure Monitoring Systems in U.S.

Bioheart, Inc. announced today that the company has signed distribution agreements with Restoration Medical, McRay Medical, Alamo Scientific and Morey Medical. These distributors will assist Bioheart with introducing its Home Heart Failure Monitoring Systems to physicians and hospitals throughout the United States.

6 Jan 2010

USPTO issues a patent to CyDex Pharmaceuticals' Captisol technology

CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled “Sulfoalkyl Ether Cyclodextrin Compositions.” This patent, along with other previously issued technology patents, will provide broad protection for CyDex’s Captisol® technology until 2029.

6 Jan 2010

IME introduces new drug-free pain relief alternative for headache

Innovative Medical Equipment, LLC. (IME) today announced the full U.S. market release of SOOTHEAWAY - a new, thermo-electrically heated and cooled therapy device that helps relieve migraine, tension or stress headache pain in the forehead, temples, occipital and ocular / sinus regions.

6 Jan 2010

Therapy News and Research

Also in global health news: ART access in Zimbabwe; Indonesia bird flu deaths; Kenya floods; Solomon Island tsunami

Physicians perform first implantation of leadless cardiac monitoring device for detecting arrhythmias

Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

Center for Technology and Aging announces grants to improve medication use in older adults

U.S. market for urological devices to reach over $5.4 billion in 2016

New survival prediction equation may impact clinical trials for treating PAH

Loyola University Health System launches new program to study healthcare, costs and patient safety

UC San Diego bioengineering professor receives 2009 Presidential Science Prize

AMT receives Innovation Credit to develop gene therapy treatment for DMD

Animal experiments show old antidepressant may reverse heart failure

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

Lerner Medical Devices' Levia receives FDA clearance

Health Canada approves Zyclara Cream for multiple actinic keratoses

Bioheart signs distribution agreements to market Home Heart Failure Monitoring Systems in U.S.

USPTO issues a patent to CyDex Pharmaceuticals' Captisol technology

IME introduces new drug-free pain relief alternative for headache

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News